Health
Combination of SFRP2 and PD-1 immunotherapy halts aggressive metastatic cancer in preclinical model – News-Medical.Net
In a cancer that has not seen new targeted therapies for over 20 years, MUSC Hollings Cancer Center researcher and oncologist…
In a cancer that has not seen new targeted therapies for over 20 years, MUSC Hollings Cancer Center researcher and oncologist Nancy Klauber-DeMore, M.D., is pioneering new discoveries.
Using a combination of personal passion and expertise, Klauber-DeMore…
Continue Reading
-
Noosa News20 hours agoThe only person detained at Brisbane’s Palestine rally
-
Noosa News22 hours agoDid you lose your ring?
-
Business24 hours agoWill GQG Partners shares rise from here? Macquarie reveals its forecast post-results
-
Noosa News21 hours agoWhy police and protesters disagree on how big Sunday’s Gaza rallies were